Ten Minutes with Your GP: How to Talk About CBD Clearly, and What the Guidance Really Covers

A general practice appointment in the UK is a short encounter. Ten minutes is a common slot, and in that time a clinician is expected to cover history, examination, risk, prescribing and follow-up. CBD rarely arrives as the main agenda item; more often it surfaces halfway through, as an aside: ‘and I have been taking CBD oil, by the way.’

The purpose of this article is not to encourage or discourage that disclosure. It is to help you make the disclosure useful. A clinician who understands exactly what you are taking, at what dose, from which product, alongside which medicines, can give you far more relevant advice than one who is told only the words ‘CBD oil’.

Before the appointment: decide what you actually want

Patients arrive at consultations with CBD for several different reasons, and they are not interchangeable:

• Reassurance about whether a product is safe alongside existing medication.
• Symptom control that has not been addressed by conventional treatment.
• A record on the notes, so that any future prescriber knows what is being used.
• A steer on whether the product they have bought is legitimate.

Knowing which of these you are seeking changes the conversation. A GP cannot validate a supplement’s quality; a pharmacist is often better placed to check interactions and product detail; a specialist prescriber is the only route to a licensed cannabidiol medicine. Being clear about the ask prevents the appointment from drifting.

Describing the product without the marketing language

Labels are written to sell. Consultations work better with plain description. Prepare a short factual summary in advance and, ideally, bring the packaging or a photograph of it.

The details that matter are:

1. Product type — oil drops, capsule, vape liquid, topical, edible, drink.
2. Cannabinoid content per unit — milligrams of CBD per drop, capsule or serving, not the total bottle size.
3. Total daily intake — how many milligrams you actually take across a day.
4. Spectrum claim — whether the label says isolate, broad-spectrum or full-spectrum.
5. THC status — whether the product states a THC content and what that figure is.
6. Batch and testing information — whether a certificate of analysis is available for the batch you hold.
7. Start date and pattern of use — daily, occasional, and whether the dose has changed.
8. Reason for use — sleep, pain, anxiety, or something else, and whether it appears to be helping.

That list is deliberately unglamorous. It is also far more clinically informative than any description copied from a product page.

The interaction question is the one that matters most

Cannabidiol is not pharmacologically inert. It is metabolised in the liver and has been shown to affect several cytochrome P450 enzymes, which means it can plausibly alter the blood levels of other medicines. The best-documented example in the clinical literature concerns clobazam, where cannabidiol has been associated with raised levels of its active metabolite. Similar concerns are routinely raised, with varying strength of evidence, about anticoagulants, certain immunosuppressants, some anti-epileptic drugs and other narrow-therapeutic-index medicines.

There are additive-effect questions too. CBD taken alongside alcohol, benzodiazepines, opioid analgesics, antihistamines or other sedating medicines may increase drowsiness. For anyone driving, operating machinery or working shifts, that is a practical concern rather than a theoretical one.

This is precisely the territory where a GP or community pharmacist can add value. Bring a full medicines list, including over-the-counter products and supplements, and ask directly: ‘Are there any medicines here where CBD could change the level or the effect?’

What UK guidance does — and does not — say

The regulatory picture in the UK is more layered than most product marketing implies.

Licensed medicine. Cannabidiol is the active ingredient in a licensed medicine, Epidyolex, authorised for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. It is initiated and supervised by specialist clinicians, not by GPs, and it is not the same product as a high-street CBD oil.

Medicines framing. Since 2016 the MHRA has taken the position that products making medicinal claims for cannabidiol fall within the definition of a medicinal product and require a marketing authorisation. Most retail CBD products therefore present themselves as food supplements and must avoid medicinal claims.

Food law. CBD extracts are treated as novel foods. The FSA has published a public list of products for which valid applications have been submitted, and has advised as a precaution that healthy adults should not exceed 10 mg of CBD per day while evidence is reviewed. Its advice also states that CBD is not appropriate for people who are pregnant or breastfeeding, or for those under 18, and that anyone taking medication should speak to a healthcare professional.

What guidance does not do is endorse CBD for any given condition, set a ‘safe’ dose for long-term use, or provide GPs with a prescribing route for retail products.

What not to expect from the appointment

• A prescription for a shop-bought product. GPs cannot prescribe unlicensed CBD products on the NHS.
• A verdict on brand quality. Your GP has no access to third-party batch testing data and no regulatory role in supplement purity.
• Dose titration advice. Guidance on starting and adjusting dose is not part of routine primary care practice for unlicensed products.
• Confirmation that online claims are true. Marketing language about inflammation, anxiety or ‘clinical strength’ is not clinical evidence.
• A guarantee of no interaction. Absence of reported problems is not the same as established safety.

Questions worth taking in

• Given my medicines, is there a meaningful interaction risk I should monitor?
• Which symptoms or side effects should prompt me to stop and seek advice?
• Should this be recorded on my notes, and how?
• Is a referral to a specialist appropriate, or is this outside NHS treatment pathways?
• How do I report a suspected adverse reaction? (In the UK, through the MHRA Yellow Card scheme.)

A short script you can adapt

‘I take [product type] containing [x] mg CBD per [unit], which is [y] mg a day, and I have taken it since [date]. I also take [medicines]. I am not asking for a prescription — I would like to know whether there is an interaction risk, and whether you think it should be recorded.’

That is a complete, honest and clinically usable statement. It fits comfortably into ten minutes.

The bottom line

A GP appointment is not the place to seek validation of a purchase, and it is not a gatekeeping exercise either. It is a chance to have your CBD use documented and reviewed alongside the rest of your medicines by someone who can see the whole picture. Treat marketing as marketing, bring specifics rather than brand loyalty, and ask the interaction question first.